Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Carl-Johan Dalsgaard Appointed New CEO of Vicore Pharma

The board of directors of Vicore Pharma Holding AB (”Vicore”) has on August 29, 2018 appointed Dr. Carl-Johan Dalsgaard as new CEO of Vicore. Carl-Johan Dalsgaard is CEO of INIM Pharma AB which was recently acquired by Vicore. He is a trained physician and PhD from the Karolinska Institute and has over 25 years of experience from drug development with Astra/AstraZeneca and several biotech companies.Carl-Johan Dalsgaard replaces Per Jansson who has been the CEO of Vicore Pharma Holding AB since 2013 and also the CEO of Vicore Pharma AB since 2007. The appointment was made in light of Vicore’

Herantis Pharma Oyj: Manager's Transactions - Antti Vuolanto

Herantis Pharma Oyj: Manager's Transactions - Antti Vuolanto Herantis Pharma PlcCompany release 30 Aug 2018 at 9:00 am Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Vuolanto, Antti Position: Other senior manager Issuer: Herantis Pharma Oyj LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number: 743700W4CQVYAT3WKK38_20180828114244_3 ____________________________________________ Transaction date: 2018-08-29 Venue not applicable

Herantis Pharma Oyj: Manager's Transactions - Pekka Mattila

Herantis Pharma Oyj: Manager's Transactions - Pekka Mattila Herantis Pharma PlcCompany release 30 Aug 2018 at 9:00 am Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Mattila, Pekka Position: Member of the Board/Deputy member Issuer: Herantis Pharma Oyj LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number: 743700W4CQVYAT3WKK38_20180828115121_2 ____________________________________________ Transaction date: 2018-08-29 Venue not

Herantis Pharma Oyj: Manager's Transactions - Aki Prihti

Herantis Pharma Oyj: Manager's Transactions - Aki Prihti Herantis Pharma PlcCompany release 30 Aug 2018 at 9:00 am Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Prihti, Aki Position: Member of the Board/Deputy member Issuer: Herantis Pharma Oyj LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number: 743700W4CQVYAT3WKK38_20180828114149_2 ____________________________________________ Transaction date: 2018-08-29 Venue not

Herantis Pharma Oyj: Manager's Transactions - Timo Veromaa

Herantis Pharma Oyj: Manager's Transactions - Timo Veromaa Herantis Pharma PlcCompany release 30 Aug 2018 at 9:00 am Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Veromaa, Timo Position: Member of the Board/Deputy member Issuer: Herantis Pharma Oyj LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number: 743700W4CQVYAT3WKK38_20180828114448_2 ____________________________________________ Transaction date: 2018-08-29 Venue not

Herantis Pharma Oyj: Manager's Transactions - Frans Wuite

Herantis Pharma Oyj: Manager's Transactions - Frans Wuite Herantis Pharma PlcCompany release 30 Aug 2018 at 9:00 am Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Wuite, Frans Position: Member of the Board/Deputy member Issuer: Herantis Pharma Oyj LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number: 743700W4CQVYAT3WKK38_20180828114648_2 ____________________________________________ Transaction date: 2018-08-29 Venue not

Herantis Pharma Oyj: Manager's Transactions - Pekka Simula

Herantis Pharma Oyj: Manager's Transactions - Pekka Simula Herantis Pharma PlcCompany release 30 Aug 2018 at 9:00 am Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Simula, Pekka Position: Chief Executive Officer Issuer: Herantis Pharma Oyj LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number: 743700W4CQVYAT3WKK38_20180828115133_3 ____________________________________________ Transaction date: 2018-08-29 Venue not applicable

Herantis Pharma Oyj: Manager's Transactions - James Phillips

Herantis Pharma Oyj: Manager's Transactions - James Phillips Herantis Pharma PlcCompany release 30 Aug 2018 at 9:00 am Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Phillips, James Position: Member of the Board/Deputy member Issuer: Herantis Pharma Oyj LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number: 743700W4CQVYAT3WKK38_20180828114932_2 ____________________________________________ Transaction date: 2018-08-29 Venue not

Readly raises €10m for next stage of global expansion; adds new investor Swedbank Robur

Readly, the global digital magazine newsstand, today announced it has raised €10m in additional funding to drive the next stage of its growth. The latest round of funding comes from new investor Swedish fund Swedbank Robur and London based Zouk Capital. The company will use the funds to further its international expansion and support growth in its existing markets. "Reading magazines digitally has become second nature as the demand for quality, curated content via the smartphone or tablet grows. The funding reflects confidence in our business model, team and market. It plays an important

Gradientech closes $2.2M Equity Funding Round

Uppsala Sweden, August 30, 2018. The Swedish biotech and diagnostics firm Gradientech has successfully raised 20 MSEK ($2.2M) in equity funding among its existing investors.Gradientech is a privately owned company developing the in vitro diagnostic (IVD) QuickMIC™ system, a promising platform based on phenotypic bacteria growth analysis. The system is expected to become the most rapid solution for diagnosing appropriate antibiotic treatment of sepsis patients. Rapid antibiotic susceptibility testing is considered essential for increasing sepsis patient survival, especially in the global

Rikshem’s half-year report for January-June 2018: Positive change in value and higher rental income

Rental income increased to MSEK 1,374 (1,335). Rental income for existing properties rose 4.5 percent (4.1). Profit after tax amounted to MSEK 1,144 (1,464).“We have signed several agreements to acquire properties for public use and our rent increases for the year are beginning to take effect. The value of the properties continued to improve and rental income continued to increase. At the same time, our earnings were impacted by the harsh winter weather and higher financial items as a result of our increased debt duration and interest-rate duration. We also maintained our long-term focus on

Eniro announces final outcome in the exchange offers

This press release may not be announced, published or distributed, in whole or in part, directly or indirectly, in the United States, Canada, Japan, Australia, Hong Kong, New Zealand, Singapore, South Africa or any other country where such publication or distribution would violate applicable laws or rules or would require additional documents to be prepared or registered or require any other actions to be taken, in addition to the requirements under Swedish law. This press release is not a prospectus. For further information, please refer to “Important information” in this press release.The

Interim report May-July 2018/19

Q1 2018/19: ·  Gross order intake amounted to SEK 3,174 M (2,738), an increase of 16 percent in SEK and 12 percent based on constant exchange rates. ·  Net sales was SEK 2,819 M (2,504), an increase of 13 percent in SEK and 10 percent based on constant exchange rates. ·  EBITA amounted to SEK 386 M (420), including a positive effect of SEK 76 M related to a divestment during the period. ·  EBITA margin was 13.7 percent (16.7). ·  Operating result was SEK 238 M (281). ·  Net income amounted to SEK 166 M (199). Earnings per share was SEK 0.43 (0.52) before/after dilution.

Bricknode Broker 2.15: White labels and updated tables

Earlier this week Bricknode released a new version of its benchmark-setting, cloudbased financial software Bricknode Broker. The new release contains a few upgrades compared to earlier versions. Most noteworthy is the new White Label Manager.Since Bricknode Broker saw the day of light back in 2015, it has served it's customers well, making the handling of securities relatively easy. But it isn't until now that Bricknode's customers can offer the same services to _their_ clients.Version 2.15 of Bricknode Broker fixes this. White Label Manager is an add-on that allows clients of

NRC Group ASA acquires Gunnar Knutsen AS

NRC Group ASA ("NRC Group" or the "Company") has on 30 August 2018 entered into a definitive agreement for the acquisition of Gunnar Knutsen AS ("GK") for an enterprise value of NOK 199 million on a cash and debt free basis. Construction and infrastructure development is associated with major climate and environmental responsibility. There is a clear trend of increased regulations and expectations from the authorities related to sustainability and environmental impact. The same trend is reflected among customers and other stakeholders, which has led to a higher weighting of environmental

PRESS RELEASE: Powerful tools from VTT to solve challenges in bio- and circular economy

VTT Technical Research Centre of Finland has developed an efficient synthetic biology toolbox for industry and research organisations. This toolbox enables, in an unprecedented way, engineering of a diverse range of yeasts and fungi. The toolbox comprises DNA parts which can be easily combined to create new biological systems. The SES (Synthetic Expression System) toolbox enables expression of genes in yeasts and fungi considerably more efficiently and with better control than has been possible with previous methods. The toolbox is based on DNA components with well-defined functions and

Sedana Medical AB (publ), Interim report Q2, 2018

The registration process for the United States commenced and European study resumed at full speedFinancial Summary April-June  ·  Net sales during the third quarter amounted to 14 485 (9 549) KSEK corresponding to an increase of 52% compared with the same period in 2017. ·  Earnings before interest, taxes, depreciation and amortisation (EBITDA) amounted to -1 006 (673) KSEK. This corresponds to an EBITDA margin of -6,9% (7,1%). ·  Earnings before interest and taxes (EBIT) amounted to -2 007 (408) KSEK, which corresponds to an EBIT margin of -13,9% (4,3%). ·  Cash flow from

Kielo completes its first acquisition in Helsinki Metropolitan Area

Helsinki, 30 August 2018 The real estate company Kielo, managed by Brunswick Real Estate, has acquired an 53,000 sqm office portfolio with three properties situated in the Helsinki Metropolitan Area ("HMA").Kielo has finalized the acquisition of a property portfolio comprising of three office assets in HMA. The portfolio was sold by NIAM. The three properties are situated in established office areas around Helsinki; Vantaankoski, Herttoniemi and Leppävaara. All buildings are modern offices constructed between 1991 and 2013. The portfolio is close to fully let to more than 40 tenants. The

Interim Financial Report - Second quarter 2018.

Q2 financial performance The second quarter (Q2) 2018 consolidated financial statement describes the operating results of the Scan Global Logistics A/S Group. · The Q2 2018 revenue was DKK 874 million and 3% above Q2 2017. · The total Q2 Gross Profit was DKK 146 million and the Gross Margin equals 16.7%. · The Q2 2018 revenue and EBITDA before special items comprise of DKK 874 million and DKK 23 million respectively. The full report can be downloaded at https://www.scangl.com/investor For further information, please contact:Allan Melgaard, Group CEOClaes

Annual results at the end of June 2018

Resilient operating results in an unfavourable context · Annual published turnover rose 0.3% to EUR 2,241.5 million (a 0.7% increase on a like-for-like basis) despite two business days less; · Slight decline in reported EBITDA to EUR 255.6 million i.e. -3.9% (down 2.1% at constant scope) and limited decrease in margin rate (11.4% vs. 11.9% the previous year); · Net profit group share of EUR 7.3 million (versus a profit of €57 million in 2017) due to exceptional restructuring charges; · Reduction in net financial debt, amounting to EUR 927.1 million at the end of June 2018 (

Blast furnace shutdown in Oxelösund

SSAB has today decided to shut down blast furnace operations at SSAB Special Steels’mill in Oxelösund. The outage is unplanned and expected to last for two weeks.The decision to shut down was made after unusually high temperatures in the mantle of the blast furnace. This will be further investigated. The blast furnace was fully refurbished as recently as 2011, with additional work completed in 2016 and was thus fitted out to last until the conversion to electric arc furnace in 2025. Necessary measures are estimated to take around two weeks, followed by the restart of the furnace. The

Hemfosa obtains approval from bondholders to a potential distribution of Nyfosa

Hemfosa Fastigheter AB (“Hemfosa”) announced on August 13, 2018 that it is, through a written procedure, soliciting approval from holders of its bonds with ISIN SE0009357403 and SE0009664337 (the “Bonds”) to amend the terms and conditions of the Bonds in relation to a potential distribution of the shares in its subsidiary Nyfosa during the fourth quarter of 2018. Hemfosa hereby announces that holders of the Bonds representing more than 50 percent of the principal amount of each Bond loan have voted to approve the proposed amendment to permit a potential distribution of the shares in

EAB Group Plc: SHARE REPURCHASE 29.8.2018

EAB GROUP Plc               ANNOUNCEMENT           29.8.2018 SHARE REPURCHASE 29.8.2018 In the Helsinki Stock Exchange Trade date 29.8.2018Bourse trade BUYShare EABGBAmount 479 sharesTotal cost 1 820,20 EURAverage price/ share 3,8000 EUR EAB Group Plc now holds a total of 18.243 sharesincluding the shares repurchased on 29.8.2018. On behalf of EAB Group Plc. Nordea Bank AB (publ), Finnish BranchJanne Sarvikivi         Ilari IsomäkiFurther information:EAB Group PlcDaniel

Orkla ASA: Trade subject to notification - treasury shares

Orkla ASA has on 29 August 2018 bought 320,000 Orkla shares through broker at an average price of NOK 70.4242 per share. Orkla's total holding of treasury shares after this transaction is 19.410.259 shares. The share buy-back programme initiated 16 July 2018 is now completed. Orkla ASAOslo, 29 August 2018Ref.:IR & Communications ManagerElise A. HeidenreichTel.: +47 951 41 147 This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

There are no items matching the current filter
There are no more items matching the current filter
Back to top